The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 19 December 2005. doi:10.1084/jem.20051047
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 202, Number 12, 1703-1713
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1328K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hegazi, R. A.F.
Right arrow Articles by Plevy, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hegazi, R. A.F.
Right arrow Articles by Plevy, S. E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CARBON MONOXIDE
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1–dependent pathway

Refaat A.F. Hegazi1, Kavitha N. Rao2, Aqila Mayle1, Antonia R. Sepulveda3, Leo E. Otterbein4, and Scott E. Plevy1,2

1 Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261
2 Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261
3 Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15261
4 Department of Surgery, Transplantation Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

CORRESPONDENCE Scott E. Plevy: sep1{at}pitt.edu

Heme oxygenase (HO)-1 and its metabolic product carbon monoxide (CO) play regulatory roles in acute inflammatory states. In this study, we demonstrate that CO administration is effective as a therapeutic modality in mice with established chronic colitis. CO administration ameliorates chronic intestinal inflammation in a T helper (Th)1-mediated model of murine colitis, interleukin (IL)-10–deficient (IL-10/) mice. In Th1-mediated inflammation, CO abrogates the synergistic effect of interferon (IFN)-{gamma} on lipopolysaccharide-induced IL-12 p40 in murine macrophages and alters IFN-{gamma} signaling by inhibiting a member of the IFN regulatory factor (IRF) family of transcription factors, IRF-8. A specific signaling pathway, not previously identified, is delineated that involves an obligatory role for HO-1 induction in the protection afforded by CO. Moreover, CO antagonizes the inhibitory effect of IFN-{gamma} on HO-1 expression in macrophages. In macrophages and in Th1-mediated colitis, pharmacologic induction of HO-1 recapitulates the immunosuppressive effects of CO. In conclusion, this study begins to elucidate potential etiologic and therapeutic implications of CO and the HO-1 pathway in chronic inflammatory bowel diseases.


Abbreviations used: CD, Crohn's disease; CO, carbon monoxide; CoPP, cobalt protoporphyrin; HO, heme oxygenase; IBD, inflammatory bowel disease; iNOS, inducible nitric oxide synthase; IRF, IFN regulatory factor; ISRE, IFN-stimulated response element; NO, nitric oxide; SnPP, tin protoporphyrin; UC, ulcerative colitis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

A toxic gas eases IBD
Heather L. Van Epps
J. Exp. Med. 2005 202: 1615. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS